{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T12:02:46Z","timestamp":1790337766805,"version":"4.1.0"},"reference-count":67,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background\/objectives<\/jats:title>\n                    <jats:p>Patients with chronic myeloid leukemia (CML) are increasingly undergoing surgical procedures as long-term survival improves with tyrosine kinase inhibitor (TKI) therapy. This narrative review aims to synthesize current evidence regarding perioperative risk assessment and management in patients with CML receiving TKIs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A literature search was conducted using structured searches of PubMed, Scopus, Web of Science, and Google Scholar for studies addressing perioperative management, anesthesia, bleeding, thrombosis, wound healing, obesity, pregnancy, and drug interactions in CML. Original studies, retrospective cohorts, case series, case reports, and narrative reviews relevant to perioperative care were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Available evidence demonstrated that perioperative risk in CML extends beyond routine hematologic parameters and is strongly influenced by TKI-specific toxicities and disease-related factors. Dasatinib showed the greatest association with platelet dysfunction and cytopenias, while nilotinib and ponatinib were linked to increased arterial and cardiovascular risk. Splenomegaly, obesity, bariatric surgery, and pregnancy further altered perioperative risk and TKI pharmacokinetics. Available evidence does not establish validated drug-specific preoperative TKI interruption intervals, and the decision regarding temporary interruption should therefore be individualized according to TKI-specific toxicity, disease status, and procedural risk. The review additionally identified clinically significant CYP3A4-mediated interactions with perioperative anesthetic, antimicrobial, and analgesic agents, suggesting preferential use of propofol-based induction and non-CYP-dependent opioids when feasible.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Perioperative management in CML requires individualized multidisciplinary planning integrating hematologic, anesthetic, surgical, and pharmacologic considerations to optimize surgical safety while maintaining disease control.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1899207","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T11:25:41Z","timestamp":1790335541000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Perioperative care of patients with chronic myeloid leukemia on tyrosine kinase inhibitors"],"prefix":"10.3389","volume":"16","author":[{"given":"Mutasim","family":"Binidris","sequence":"first","affiliation":[{"name":"Department of Medical Education, Hamad Medical Corporation","place":["Doha, Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"\u017d\u00e1\u010dkov\u00e1","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine - Hematology and Oncology, University Hospital Brno and Masaryk University","place":["Brno, Czechia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasha","family":"Kaddoura","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Heart Hospital, Hamad Medical Corporation","place":["Doha, Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rola","family":"Ghasoub","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, National Center for Cancer Care and Research, Hamad Medical Corporation","place":["Doha, Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet Emre","family":"E\u015fkazan","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, Cerrahpa\u015fa Faculty of Medicine, Istanbul University-Cerrahpa\u015fa","place":["Istanbul, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Saglio","sequence":"additional","affiliation":[{"name":"Department of Clinical and Biological Sciences, University of Turin","place":["Turin, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Yassin","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Center for Cancer Care and Research, Hamad Medical Corporation","place":["Doha, Qatar"]},{"name":"College of Medicine, Qatar University","place":["Doha, Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.0220","article-title":"Chronic myeloid leukemia: a review","volume":"333","author":"Jabbour","year":"2025","journal-title":"JAMA"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.17849\/insm-52-3-1-7.2","article-title":"Chronic myeloid leukemia \u2013 a review of current status","volume":"52","author":"Titcomb","year":"2025","journal-title":"J Insur Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/sj.leu.2403241","article-title":"JAK\/STAT, Raf\/MEK\/ERK, PI3K\/Akt and BCR-ABL in cell cycle progression and leukemogenesis","volume":"18","author":"Steelman","year":"2004","journal-title":"Leukemia"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14010215","article-title":"BCR-ABL1 tyrosine kinase complex signaling transduction: challenges to overcome resistance in chronic myeloid leukemia","volume":"14","author":"Amarante-Mendes","year":"2022","journal-title":"Pharmaceutics"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-02664-w","article-title":"2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia","volume":"39","author":"Apperley","year":"2025","journal-title":"Leukemia"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1159\/000551493","article-title":"Chronic myeloid leukemia: historical perspective, pathophysiology, and treatment advances","author":"Tungjitviboonkun","year":"2026","journal-title":"Acta Haematol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.bvth.2024.100026","article-title":"Perioperative outcomes in patients with myeloproliferative neoplasms: a multicentric analysis of 354 surgical procedures","volume":"1","author":"Szuber","year":"2024","journal-title":"Blood Vessels Thromb Hemost"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1616883","article-title":"A deep dive into the surgical and pharmacological considerations of obesity in chronic myeloid leukemia: a narrative review","volume":"15","author":"Ghasoub","year":"2025","journal-title":"Front Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19030898","article-title":"Understanding splenomegaly in myelofibrosis: association with molecular pathogenesis","volume":"19","author":"Song","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s00464-012-2314-4","article-title":"Laparoscopic splenectomy for massive splenomegaly in benign hematological diseases","volume":"26","author":"Al-Mulhim","year":"2012","journal-title":"Surg Endosc"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1177\/1076029619866925","article-title":"Tyrosine kinase inhibitor\u2013associated platelet dysfunction: does this need to have a significant clinical impact","volume":"25","author":"Ozgur Yurttas","year":"2019","journal-title":"Clin Appl Thromb"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-024-01428-6","article-title":"Clinical pharmacology of asciminib: a review","volume":"63","author":"Hoch","year":"2024","journal-title":"Clin Pharmacokinet"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0294438","article-title":"Differential vascular endothelial cell toxicity of established and novel BCR-ABL tyrosine kinase inhibitors","volume":"18","author":"Wang","year":"2023","journal-title":"PloS One"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s11010-024-05070-5","article-title":"The BCR::ABL1 tyrosine kinase inhibitors ponatinib and nilotinib differentially affect endothelial angiogenesis and signalling","volume":"480","author":"Zibrova","year":"2025","journal-title":"Mol Cell Biochem"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.bvth.2025.100127","article-title":"Distinct endothelial cell toxicities of Abl tyrosine kinase inhibitors lead to arterial thrombosis","volume":"3","author":"Travers","year":"2025","journal-title":"Blood Vessels Thromb Hemost"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2022.100968","article-title":"Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - what to look for when treatment-free remission is not an option","volume":"56","author":"Lipton","year":"2022","journal-title":"Blood Rev"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33119","article-title":"Risk of QTc prolongation among cancer patients treated with tyrosine kinase inhibitors","volume":"147","author":"Abu Rmilah","year":"2020","journal-title":"Int J Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.2687","article-title":"Varying effects of tyrosine kinase inhibitors on platelet function-a need for individualized CML treatment to minimize the risk for hemostatic and thrombotic complications","volume":"9","author":"Deb","year":"2020","journal-title":"Cancer Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1177\/1076029619858409","article-title":"TKI-related platelet dysfunction does not correlate with bleeding in patients with chronic phase-chronic myeloid leukemia with complete hematological response","volume":"25","author":"Sener","year":"2019","journal-title":"Clin Appl Thromb"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01132","article-title":"Management of chronic myeloid leukemia in advanced phase","volume":"9","author":"Bonifacio","year":"2019","journal-title":"Front Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-015-0258-1","article-title":"Milestones and monitoring","volume":"10","author":"Morotti","year":"2015","journal-title":"Curr Hematol Malig Rep"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13933","article-title":"Haematological adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukaemia: a network meta\u2010analysis","volume":"85","author":"Fachi","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15174354","article-title":"Hematological adverse events with tyrosine kinase inhibitors for chronic myeloid leukemia: a systematic review with meta-analysis","volume":"15","author":"Kronick","year":"2023","journal-title":"Cancers"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2022.101353","article-title":"Thrombosis and bleeding in hematological malignancy","volume":"35","author":"Wang","year":"2022","journal-title":"Best Pract Res Clin Haematol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2147\/BLCTT.S125121","article-title":"Complications and management of coagulation disorders in leukemia patients","volume":"7","author":"Lad","year":"2017","journal-title":"Blood Lymphat Cancer Targets Ther"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.88032","article-title":"Splenic infarction at the crossroads of hematologic and cardioembolic risk","volume":"17","author":"Annan","year":"2025","journal-title":"Cureus"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/jscr\/rjaf485","article-title":"Surgical management of giant splenomegaly in chronic myeloid leukemia: a challenging splenectomy case","volume":"2025","author":"Alqatta","year":"2025","journal-title":"J Surg Case Rep"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01238-w","article-title":"Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape","volume":"35","author":"Hsieh","year":"2021","journal-title":"Leukemia"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25246","article-title":"Splenectomy in patients with chronic myelomonocytic leukemia: indications, histopathological findings and clinical outcomes in a single institutional series of 39 patients","volume":"93","author":"Pophali","year":"2018","journal-title":"Am J Hematol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2017.1264797","article-title":"Recommended vaccinations for asplenic and hyposplenic adult patients","volume":"13","author":"Bonanni","year":"2016","journal-title":"Hum Vaccines Immunother"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006911","article-title":"How to manage CML patients with comorbidities","volume":"136","author":"Cortes","year":"2020","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13944","article-title":"Tyrosine kinase inhibitors and vascular adverse events in patients with chronic myeloid leukemia: a population\u2010based, propensity score\u2010matched cohort study","volume":"26","author":"Chen","year":"2021","journal-title":"Oncologist"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2025.06.007","article-title":"Cardiovascular disease in patients with chronic myeloid leukemia: JACC: CardioOncology state-of-the-art review","volume":"7","author":"Aghel","year":"2025","journal-title":"JACC CardioOncology"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad225","article-title":"Association of nilotinib with cardiovascular diseases in patients with chronic myelogenous leukemia: a national population-based cohort study","volume":"29","author":"Huang","year":"2024","journal-title":"Oncologist"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s40199-019-00321-z","article-title":"Pharmacology of tyrosine kinase inhibitors in chronic myeloid leukemia; a clinician\u2019s perspective","volume":"28","author":"Pushpam","year":"2020","journal-title":"DARU J Pharm Sci"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-018-0449-7","article-title":"Tyrosine kinase inhibitors in the treatment of chronic phase CML: strategies for frontline decision-making","volume":"13","author":"Kennedy","year":"2018","journal-title":"Curr Hematol Malig Rep"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-01829-9","article-title":"Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL","volume":"37","author":"Hochhaus","year":"2023","journal-title":"Leukemia"},{"key":"B39","doi-asserted-by":"publisher","first-page":"LBA6500","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA6500","article-title":"ASC4FIRST, a pivotal phase 3 study of asciminib (ASC) vs investigator-selected tyrosine kinase inhibitors (IS TKIs) in newly diagnosed patients (pts) with chronic myeloid leukemia (CML): primary results","volume":"42","author":"Hughes","year":"2024","journal-title":"J Clin Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/iwj.70513","article-title":"The adverse impact of tyrosine kinase inhibitors on wound healing and repair","volume":"22","author":"Nahm","year":"2025","journal-title":"Int Wound J"},{"key":"B41","volume-title":"Rowland and Tozer\u2019s Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications","author":"Derendorf","year":"2020"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-020-00872-4","article-title":"Clinical pharmacokinetics and pharmacodynamics of dasatinib","volume":"59","author":"Lev\u00eaque","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3390\/hematolrep17050047","article-title":"Tyrosine kinase inhibitor treatment of a patient with chronic myeloid leukemia and congenital thrombophilia","volume":"17","author":"Herrera-Hern\u00e1ndez","year":"2025","journal-title":"Hematol Rep"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-3413-7","article-title":"Drug-to-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia patients. is it a real problem","volume":"97","author":"Osorio","year":"2018","journal-title":"Ann Hematol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0027019","article-title":"Anesthetic propofol attenuates the isoflurane-induced caspase-3 activation and A\u03b2 oligomerization","volume":"6","author":"Zhang","year":"2011","journal-title":"PloS One"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2018.08.063","article-title":"Volatile anesthetics sevoflurane targets leukemia stem\/progenitor cells via Wnt\/\u03b2-catenin inhibition","volume":"107","author":"Ruan","year":"2018","journal-title":"BioMed Pharmacother"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1159\/000524538","article-title":"Safety of intraoperative cell salvage in cancer surgery: an updated meta-analysis of the current literature","volume":"49","author":"Frietsch","year":"2022","journal-title":"Transfus Med Hemotherapy"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18275","article-title":"Haematological management of major haemorrhage: a British Society for Haematology guideline","volume":"198","author":"Stanworth","year":"2022","journal-title":"Br J Haematol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00160-7","article-title":"2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19","volume":"23","author":"Farge","year":"2022","journal-title":"Lancet Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1159\/000550346","article-title":"Evaluating the safety of combining tyrosine kinase inhibitors with anticoagulants in chronic myeloid leukemia: a systematic review","volume":"104","author":"Gameil","year":"2026","journal-title":"Oncology"},{"key":"B51","doi-asserted-by":"publisher","first-page":"15272","DOI":"10.1038\/s41598-019-51548-4","article-title":"Complications associated with perioperative use of tyrosine kinase inhibitor in cytoreductive nephrectomy","volume":"9","author":"Carvalho","year":"2019","journal-title":"Sci Rep"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15153781","article-title":"Patients undergoing systemic anti-cancer therapy who require surgical intervention: What surgeons need to know","volume":"15","author":"Robinson","year":"2023","journal-title":"Cancers"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-025-03151-w","article-title":"Tyrosine kinase inhibitors - balancing the haemostatic scales: a review of associated thrombosis and bleeding","author":"Butel-Simoes","year":"2025","journal-title":"J Thromb Thrombolysis"},{"key":"B54","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1080\/08998280.2009.11928458","article-title":"Postsplenectomy reactive thrombocytosis","volume":"22","author":"Khan","year":"2009","journal-title":"Proc Bayl Univ Med Cent"},{"key":"B55","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1007\/s12094-012-0767-5","article-title":"Tyrosine kinase inhibitors and drug interactions: a review with practical recommendations","volume":"14","author":"Pajares","year":"2012","journal-title":"Clin Transl Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70579-5","article-title":"Drug\u2013drug interactions with tyrosine-kinase inhibitors: a clinical perspective","volume":"15","author":"van Leeuwen","year":"2014","journal-title":"Lancet Oncol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae094","article-title":"Opioid metabolism and drug-drug interaction in cancer","volume":"29","author":"Aapro","year":"2024","journal-title":"Oncologist"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S179902","article-title":"Post-splenectomy sepsis: preventative strategies, challenges, and solutions","volume":"12","author":"Luu","year":"2019","journal-title":"Infect Drug Resist"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0891","article-title":"Cardiotoxicity monitoring in patients treated with tyrosine kinase inhibitors","volume":"24","author":"Skubitz","year":"2019","journal-title":"Oncologist"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02183-0","article-title":"Chronic myeloid leukemia diagnosed in pregnancy: management and outcome of 87 patients reported to the European LeukemiaNet international registry","volume":"38","author":"Chelysheva","year":"2024","journal-title":"Leukemia"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34725","article-title":"Association between bariatric surgery and outcomes in chronic myeloid leukemia","volume":"129","author":"Haddad","year":"2023","journal-title":"Cancer"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.3738","article-title":"How I treat obesity and obesity related surgery in patients with chronic myeloid leukemia: An outcome of an ELN project","volume":"9","author":"Yassin","year":"2021","journal-title":"Clin Case Rep"},{"key":"B63","doi-asserted-by":"publisher","first-page":"499","DOI":"10.55729\/2000-9666.1428","article-title":"Spontaneous splenic rupture leading to the diagnosis of CML","volume":"15","author":"Dahake","year":"2025","journal-title":"J Community Hosp Intern Med Perspect"},{"key":"B64","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1186\/s13256-024-04744-4","article-title":"Leukocytosis and thrombocytosis after splenectomy: expected finding, infection, or something else: a case report","volume":"18","author":"Gonzalez","year":"2024","journal-title":"J Med Case Rep"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/3138718","article-title":"Chronic myeloid leukemia and cesarean section: The anesthesiologist\u2019s point of view","volume":"2018","author":"Rebahi","year":"2018","journal-title":"Case Rep Obstet Gynecol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijoa.2015.11.004","article-title":"Chronic myeloid leukemia in pregnancy: an absolute contraindication to neuraxial anesthesia","volume":"25","author":"Owsiak","year":"2016","journal-title":"Int J Obstet Anesth"},{"key":"B67","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.critrevonc.2005.03.004","article-title":"Surgical interventions in patients with hematologic malignancies","volume":"55","author":"Hohenberger","year":"2005","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1899207\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T11:25:42Z","timestamp":1790335542000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1899207\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":67,"alternative-id":["10.3389\/fonc.2026.1899207"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1899207","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]},"article-number":"1899207"}}